Market by Therapeutics, Diagnostics, and Country Outlook | Forecast 2022-2028
As per Triton Market Research, the Latin America Alzheimer’s disease therapeutics and diagnostics market is likely to grow with a CAGR of 6.19% over the estimated period between 2022 and 2028.
Report scope can be customized per your requirements. Request For Customization
The
countries analyzed in this region include:
•
Mexico
•
Brazil
•
Rest of Latin America
Various countries in
the region are initiating national-level healthcare plans for dementia patients.
However, they encounter substantial challenges when it comes to providing an
accurate dementia diagnosis and effective care. Overall though, the market for Alzheimer’s
disease therapeutics and diagnostics is expected to observe steady growth over
the considered period.
Data from the World
Population Ageing 2019 report suggests that there were nearly 19.526 million
people in Brazil aged 65 years or older, as of 2019. By 2030, it is expected that
nearly 30.413 million will fall in this age group. The older population is
predicted to increase over the coming years, and thus, the demand for AD
therapeutics and diagnostics is anticipated to expand. This is because they are
more prone to neurological conditions like Alzheimer’s disease and dementia.
In Rest of Latin
America, the rising number of awareness campaigns by government as well as
non-government organizations are anticipated to increase the demand for early
disease detection and treatment. This is expected to drive the market’s
expansion. For instance, in Chile, the Corporacion Alzheimer Chile is working
towards educating the public about Alzheimer’s disease. These factors are
expected to foster the studied market’s growth in the coming years.
At the prodromal
disease stage, there are evident signs of brain dysfunction. Aducanumab and
other candidate A vaccines will be recommended for the treatment of prodromal
and mild AD if they receive approval. According to a 2020 Practical Neurology
article, mild cognitive impairment is another name for the prodromal stage of
Alzheimer’s disease (MCI).
The
report assesses the market according to therapeutics and diagnostics. Here,
the therapeutics segment comprises disease stage, drug type, and generic &
branded. Disease stage is further classified into late stage: severe AD, early/middle
stage: mild to moderate AD, and prodromal stage.
The
noteworthy players in the Alzheimer’s disease therapeutics and diagnostics
market include Teva Pharmaceutical Industries Ltd, Merck and Co, Johnson and
Johnson, Baxter International Inc, Allergan Plc (acquired by Abbvie), Amarantus
Bioscience Holdings Inc, Sun Pharmaceuticals Industries Ltd, Novartis AG, and
Eisai Co Ltd.
Johnson and Johnson is
an investment holding company with a focus on healthcare items. It is engaged
in developing, manufacturing, and marketing surgical equipment,
pharmaceuticals, and personal care items. Pharmaceuticals, Medical Devices, and
Consumer are the three business segments through which the company operates. Galantamine
is approved to treat the symptoms of mild to moderate Alzheimer’s disease, such
as memory loss. In the United States, it is sold under the brand names Razadyne
and Razadyne ER. The company was founded in 1886 and has a vast business
experience. The company has established R&D facilities in several
countries, including Brazil.
Key deliverables of the report:
·
Market
CAGR during the forecasting years 2022-2028
·
Detailed
data highlighting key insights, industry components, and market strategies
·
Comprehensive
information and estimation of the Alzheimer’s disease therapeutics and
diagnostics market revenue growth in Latin America and its influence on the
parent market
·
In-depth
study of forthcoming trends in consumer behavioral patterns
·
A
meticulous analysis of the competitive landscape, vendor scorecard, and
Porter’s Five Forces Model
·
A
wide-ranging study of factors that will challenge the Latin America Alzheimer’s
disease therapeutics and diagnostics market’s growth during the upcoming years
Want
to get specific insights? Our team of analysts can customize this report based
on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. TIMELINE
OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.2. PHASES
AND STERNNESS OF ALZHEIMER’S DISEASE
2.3. KEY
INSIGHTS
2.3.1. USAGE
OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE
2.3.2. R&D
INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.3.3. DEMAND
FOR PERSONALIZED MEDICINES
2.4. IMPACT
OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.5. PORTER’S
FIVE FORCES ANALYSIS
2.6. MARKET
ATTRACTIVENESS MATRIX
2.7. VENDOR
SCORECARD
2.8. INDUSTRY
COMPONENTS
2.8.1. RESEARCH
& DEVELOPMENT (R & D)
2.8.2. RAW
MATERIALS
2.8.3. MANUFACTURING
2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS
2.8.5. END-USER
2.9. KEY
IMPACT ANALYSIS
2.9.1. EFFECTIVENESS
2.9.2. PRICE
2.9.3. SAFETY
2.10. KEY
MARKET STRATEGIES
2.10.1. ACQUISITIONS
2.10.2. PRODUCT
LAUNCHES
2.10.3. CONTRACTS
& AGREEMENTS
2.10.4. INVESTMENTS
& EXPANSIONS
2.11. MARKET
DRIVERS
2.11.1. PREVALENCE
OF ALZHEIMER’S DISEASE
2.11.2. RISE
IN THE ELDERLY POPULATION
2.12. MARKET
CHALLENGES
2.12.1. FAILURE
OF LATE-STAGE DRUGS
2.12.2. STRINGENT
GOVERNMENT REGULATIONS
2.13. MARKET
OPPORTUNITIES
2.13.1. EMERGENCE
OF NEW DIAGNOSTIC TECHNOLOGIES
2.13.2. GROWING
NUMBER OF PIPELINE DRUGS
3. LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY
THERAPEUTICS
3.1. BY
DRUG TYPE
3.1.1. MARKETED
DRUGS
3.1.2. PIPELINE
DRUGS
3.2. BY
DISEASE STAGE
3.2.1. LATE
STAGE: SEVERE AD
3.2.2. EARLY/MIDDLE
STAGE: MILD TO MODERATE AD
3.2.3. PRODROMAL
STAGE
3.3. BY
GENERIC & BRANDED
3.3.1. BRANDED
3.3.2. GENERIC
4. LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY
DIAGNOSTICS
4.1. LUMBAR
PUNCTURE TEST
4.2. POSITRON
EMISSION TOMOGRAPHY
4.3. ELECTROENCEPHALOGRAPHY
4.4. MAGNETIC
RESONANCE IMAGING
4.5. COMPUTED
TOMOGRAPHY
4.6. BLOOD
TEST
4.7. OTHER
DIAGNOSTICS
5. LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – COUNTRY
OUTLOOK
5.1. BRAZIL
5.2. MEXICO
5.3. REST
OF LATIN AMERICA
6. COMPETITIVE
LANDSCAPE
6.1. BAXTER
INTERNATIONAL INC
6.2. F.
HOFFMANN-LA ROCHE AG
6.3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
6.4. NOVARTIS
AG
6.5. PFIZER
INC
6.6. SIEMENS
HEALTHINEERS AG
6.7. AMARANTUS
BIOSCIENCE HOLDINGS INC
6.8. EISAI
CO LTD
6.9. ELI
LILLY & COMPANY
6.10. LUPIN
LIMITED
6.11. MERCK
AND CO
6.12. BIOGEN
INC
6.13. COGNOPTIX
INC
6.14. GE
HEALTHCARE
6.15. JOHNSON
AND JOHNSON
6.16. SUN
PHARMACEUTICALS INDUSTRIES LTD
6.17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
6.18. ZYDUS
CADILA
7. METHODOLOGY
& SCOPE
7.1. RESEARCH
SCOPE
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE 1: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2022-2028 (IN $ MILLION)
TABLE 2: MARKET
ATTRACTIVENESS MATRIX
TABLE 3: VENDOR
SCORECARD
TABLE 4: KEY STRATEGIC
DEVELOPMENTS
TABLE 5: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS,
2022-2028 (IN $ MILLION)
TABLE 6: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 7: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $
MILLION)
TABLE 8: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028
(IN $ MILLION)
TABLE 9: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS,
2022-2028 (IN $ MILLION)
TABLE 10: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2022-2028 (IN $ MILLION)
FIGURE 1: PORTER’S FIVE
FORCES ANALYSIS
FIGURE 2: KEY IMPACT
ANALYSIS
FIGURE 3: TIMELINE OF
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
FIGURE 4: INDUSTRY
COMPONENTS
FIGURE 5: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021
& 2028 (IN %)
FIGURE 6: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 & 2028 (IN %)
FIGURE 7: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 8: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 9: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021 & 2028 (IN
%)
FIGURE 10: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD,
2022-2028 (IN $ MILLION)
FIGURE 11: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO
MODERATE AD, 2022-2028 (IN $ MILLION)
FIGURE 12: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028 (IN $
MILLION)
FIGURE 13: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2021
& 2028 (IN %)
FIGURE 14: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $
MILLION)
FIGURE 15: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $
MILLION)
FIGURE 16: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
DIAGNOSTICS, 2021 & 2028 (IN %)
FIGURE 17: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST,
2022-2028 (IN $ MILLION)
FIGURE 18: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION
TOMOGRAPHY, 2022-2028 (IN $ MILLION)
FIGURE 19: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY,
2022-2028 (IN $ MILLION)
FIGURE 20: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING,
2022-2028 (IN $ MILLION)
FIGURE 21: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY,
2022-2028 (IN $ MILLION)
FIGURE 22: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $
MILLION)
FIGURE 23: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028
(IN $ MILLION)
FIGURE 24: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY
OUTLOOK, 2021 & 2028 (IN %)
FIGURE 25: BRAZIL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 26: MEXICO
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 27: REST OF
LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028
(IN $ MILLION)